A Phase 2/3 interventional study of Tadalafil in Duchenne Muscular Dystrophy, sponsored by University of Florida. Completed at 1 site in United States. Open to male participants aged 6 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University of Florida · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 127th largest by enrollment of the 172 interventional ones that give a count, is one of 12 that started in 2021, is one of 8 in phase 2/3, and was the 177th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 13 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 91 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 172 interventional studies, 75 across the 55 observational. Of the 161 that completed or were terminated, 78 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 233 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 9 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
18 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05016908Massachusetts General HospitalExtracellular RNA Biomarkers of Duchenne Muscular Dystrophy | 2026-12 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project will assess the vascular responsiveness in leg muscles of boys with Duchenne muscular dystrophy (DMD) to one single dose of tadalafil, a common vasodilator drug, using non-invasive techniques (MRI or Doppler ultrasound). These findings will provide proof of concept for a subsequent intervention study to demonstrate efficacy of longer-term tadalafil to counter sympathetic vasoconstriction and slow disease progression in DMD.
This project will target up to 25 ambulatory boys with DMD aged 7-30 years. Because the vascular impact of tadalafil is immediate, we will confirm that the drug target is valid target in lower extremities by assessing the change in post-exercise microvascular perfusion using Blood Oxygen Level-Dependent (BOLD) MRI or change in post-exercise hyperemia using Doppler ultrasonography. Patients will be randomized to undergo the above-mentioned assessments with or without the study drug on two separate visits.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will use BOLD-MRI as the technique to monitor drug impact on skeletal muscle.
Drug: Tadalafil
Patient will be randomized to one dose of 0.6 mg/kg tadalafil on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.
Also known as: Cialis
Percent Change in Post-contractile BOLD Signal Relative to Resting Condition
The post contractile blood oxygen level-dependent (BOLD) response is a non-invasive index of microvascular function in muscle using MRI. BOLD images are acquired from the tibialis anterior before and after dorsiflexion exercise. A transient increase in BOLD signal is expected after performing a brief muscle contraction (reflecting increased small vessel oxygen saturation and blood volume). In healthy boys, MRI-BOLD signal was on average 4.4% above resting levels. The greater the value, the more intact the physiological response to muscle contraction. Previous study has reported MRI-BOLD to be on average 2.3% above rest in boys with DMD. We measured the post-contractile BOLD response twice in each participant; once after taking tadalafil (a vasodilator proposed to increase blood flow and microvascular perfusion) and once without taking the tadalafil. The order of assessment was randomized.
Time frame: MRI will be done 3 hours after dosing/no-dosing on two separate study visits
| Milestone | Tadalafil Then No Intervention | No Intervention Then Study Drug |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Tadalafil Then No Intervention | No Intervention Then Study Drug |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
The post contractile blood oxygen level-dependent (BOLD) response is a non-invasive index of microvascular function in muscle using MRI. BOLD images are acquired from the tibialis anterior before and after dorsiflexion exercise. A transient increase in BOLD signal is expected after performing a brief muscle contraction (reflecting increased small vessel oxygen saturation and blood volume). In healthy boys, MRI-BOLD signal was on average 4.4% above resting levels. The greater the value, the more intact the physiological response to muscle contraction. Previous study has reported MRI-BOLD to be on average 2.3% above rest in boys with DMD. We measured the post-contractile BOLD response twice in each participant; once after taking tadalafil (a vasodilator proposed to increase blood flow and microvascular perfusion) and once without taking the tadalafil. The order of assessment was randomized.
| percentage of BOLD signal change aseline | Tadalafil Dose | No Dose |
|---|---|---|
| Percent Change in Post-contractile BOLD Signal Relative to Resting Condition | 3.2 ± 0.9 | 2.3 ± 1.4 |
Collected over Adverse events were collected for 48 hours per patient.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil Visit | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Placebo Visit | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Event | Tadalafil Visit | Placebo Visit |
|---|---|---|
| HeadacheGeneral disorders | 5/12 | 0/12 |
| Facial flushingSkin and subcutaneous tissue disorders | 2/12 | 0/12 |
| Age, Categorical(Participants) | BOLD-MRI on and Off Study-drug |
|---|---|
| <=18 years | 12 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(Years) | BOLD-MRI on and Off Study-drug |
|---|---|
| Mean | 9.75 ± 2.6 |
| Sex: Female, Male(Participants) | BOLD-MRI on and Off Study-drug |
|---|---|
| Female | 0 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | BOLD-MRI on and Off Study-drug |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | BOLD-MRI on and Off Study-drug |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | BOLD-MRI on and Off Study-drug |
|---|---|
| United States | 11 |
| Finland | 1 |
| Weight(Kg) | BOLD-MRI on and Off Study-drug |
|---|---|
| Mean | 33.3 ± 8.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Apr 2024, 28 months.
Results were first posted in Oct 2026, 2 years 6 months after primary completion.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Apr 2024, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil
Muscular Dystrophy, Duchenne →